UA74335C2 - Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну - Google Patents

Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну

Info

Publication number
UA74335C2
UA74335C2 UA2001128821A UA2001128821A UA74335C2 UA 74335 C2 UA74335 C2 UA 74335C2 UA 2001128821 A UA2001128821 A UA 2001128821A UA 2001128821 A UA2001128821 A UA 2001128821A UA 74335 C2 UA74335 C2 UA 74335C2
Authority
UA
Ukraine
Prior art keywords
controlled release
serotonin reuptake
selective serotonin
release formulation
formulation containing
Prior art date
Application number
UA2001128821A
Other languages
English (en)
Russian (ru)
Inventor
Тереза Енн Джері
Кетрін Енн Морріссей
Пол Старк
Original Assignee
Елан Корпорейшн, Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27620490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA74335(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елан Корпорейшн, Плс filed Critical Елан Корпорейшн, Плс
Priority claimed from PCT/IE2000/000060 external-priority patent/WO2000071099A1/en
Publication of UA74335C2 publication Critical patent/UA74335C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Мультичастинкова композиція контрольованого вивільнення селективного інгібітору зворотного захоплення серотоніну (SSRI) для перорального введення, яка включає частинки, що складаються з ядра, яке містить флувоксамін або його фармацевтично прийнятну сіль, і покриття, що забезпечує контрольоване вивільнення вказаного SSRI протягом періоду часу не менше, ніж приблизно 12 годин, після перорального введення. Композиція придатна для одноразового або дворазового прийому на день. Композиція може містити суміш двох або більше видів частинок, гранул або міні-таблеток, які мають різні характеристики вивільнення in vitro та/або in vivo.
UA2001128821A 1999-05-20 2000-05-10 Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну UA74335C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13502899P 1999-05-20 1999-05-20
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
PCT/IE2000/000060 WO2000071099A1 (en) 1999-05-20 2000-05-10 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Publications (1)

Publication Number Publication Date
UA74335C2 true UA74335C2 (uk) 2005-12-15

Family

ID=27620490

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001128821A UA74335C2 (uk) 1999-05-20 2000-05-10 Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну

Country Status (4)

Country Link
US (2) US7465462B1 (uk)
IE (1) IE990406A1 (uk)
UA (1) UA74335C2 (uk)
ZA (1) ZA200110401B (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
CA2598273A1 (en) * 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2010138439A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN102579406A (zh) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸氯米帕明缓释胶囊及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
PL337799A1 (en) 1997-07-01 2000-09-11 Pfizer Prod Inc Sertralin dosage forms of retarded release
IL152330A0 (en) 1997-07-01 2003-05-29 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6599529B1 (en) * 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles

Also Published As

Publication number Publication date
US7465462B1 (en) 2008-12-16
IE990406A1 (en) 2000-12-27
US20080206335A1 (en) 2008-08-28
ZA200110401B (en) 2003-03-03

Similar Documents

Publication Publication Date Title
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
MY126555A (en) Oral pharmaceutical extended release dosage form
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
BG104619A (en) Oral pharmaceutical pulsed release dosage form
DE69417733D1 (de) Verfahren zur hemmung des knochenschwundes mit 3,4-diarylchroman
HUP0002296A2 (hu) Sertralinsók és a sertralin elnyújtott felszabadulását biztosító dózisformák
ZA969945B (en) Long-lasting release nifedipine preparation
AU5408098A (en) Oral morphine multiparticulate formulation
MY106259A (en) 2-aminopyrimidinone derivatives.
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
IL211075A (en) Multi-component preparation with irregular release
CY1107750T1 (el) Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης
AR003463A1 (es) Una formulacion de liberacion controlada o de liberacion retardada; su utilizacion en la fabricacion de un medicamento y un procedimiento para su preparacion.
AU7239996A (en) Inhibition of tumor necrosis factor alpha
TNSN08018A1 (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
CA2494015A1 (en) Antibiotic product, use and formulation thereof
ES2130081A1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
UA74335C2 (uk) Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну
AP2001002233A0 (en) Particulate composition of eletriptan
Hawley et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
AU3071300A (en) Multiparticulate bisoprolol formulation
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
JP2003500348A5 (uk)
SG145717A1 (en) Composition for releasing a weak base for an extended period of time